Table 1. Single factor comparison of basic information between patients in the pancreatitis group and the control group.

| **Variables** | **Total (n = 321)** | **Pancreatitis** | | **p** |
| --- | --- | --- | --- | --- |
| **NO (n = 263)** | **YES (n = 58)** |
| sex, n (%) |  |  |  | 0.404 |
| female | 131 (41) | 104 (40) | 27 (47) |  |
| male | 190 (59) | 159 (60) | 31 (53) |  |
| age, Median (Q1,Q3) | 5.25 (3.5, 8.66) | 5 (3.5, 8.5) | 5.74 (3.87, 9.83) | 0.207 |
| weight, Median (Q1,Q3) | 18.7 (14.9, 28) | 18.3 (14.55, 27.85) | 20 (15.72, 30.12) | 0.272 |
| immunophenotype, n (%) |  |  |  | 0.106 |
| T | 26 (8) | 18 (7) | 8 (14) |  |
| B | 295 (92) | 245 (93) | 50 (86) |  |
| MRD.after.induction, Median (Q1,Q3) | 0 (0, 1.2) | 0 (0, 1.2) | 0 (0, 1.5) | 0.103 |
| asparaginase, Median (Q1,Q3) | 7500 (4000, 10000) | 8000 (5000, 12000) | 4500 (2500, 7500) | < 0.001 |
| infection, n (%) |  |  |  | 0.019 |
| NO | 236 (74) | 201 (76) | 35 (60) |  |
| YES | 85 (26) | 62 (24) | 23 (40) |  |
| pancreatic.morphology, n (%) |  |  |  | 0.015 |
| NO | 301 (94) | 251 (95) | 50 (86) |  |
| YES | 20 (6) | 12 (5) | 8 (14) |  |
| ALB, Median (Q1,Q3) | 39.3 (35.6, 42.7) | 40.3 (36.25, 43.2) | 36.2 (34.42, 38.75) | < 0.001 |
| BUN, Median (Q1,Q3) | 4.69 (3.72, 5.96) | 4.55 (3.59, 5.83) | 5.53 (4.44, 7.51) | < 0.001 |
| CR, Median (Q1,Q3) | 23.8 (19.6, 30.3) | 22.9 (19.25, 29.45) | 27.55 (22.02, 32.72) | 0.004 |
| cholesterol, Median (Q1,Q3) | 3.55 (2.95, 4.24) | 3.55 (2.95, 4.22) | 3.58 (2.8, 4.26) | 0.922 |
| calcium, Median (Q1,Q3) | 2.27 (2.19, 2.37) | 2.27 (2.19, 2.37) | 2.26 (2.16, 2.35) | 0.473 |
| AST, Median (Q1,Q3) | 29.2 (22.4, 41.3) | 29 (22.7, 38.9) | 29.6 (20.18, 48.78) | 0.495 |
| ALT, Median (Q1,Q3) | 28.9 (17.7, 51.6) | 28.9 (17.05, 51.25) | 27.8 (19.92, 54.8) | 0.496 |
| rGT, Median (Q1,Q3) | 23.2 (16.9, 44.2) | 22.7 (16.6, 42.15) | 29.35 (17.4, 63.7) | 0.082 |
| total.bilirubin, Median (Q1,Q3) | 9.73 (7.22, 13.78) | 8.91 (6.9, 12.07) | 15.62 (11.39, 22.65) | < 0.001 |
| direct.bilirubin, Median (Q1,Q3) | 1.21 (0.74, 1.87) | 1.02 (0.69, 1.69) | 2.3 (1.66, 3.68) | < 0.001 |
| bile.acid, Median (Q1,Q3) | 6.5 (3.52, 12.15) | 6.22 (3.51, 11.06) | 7.84 (3.86, 17.15) | 0.042 |
| triglyceride, Median (Q1,Q3) | 1.33 (0.94, 2.03) | 1.33 (1, 2.08) | 1.23 (0.78, 1.9) | 0.094 |
| LDL.C, Median (Q1,Q3) | 1.8 (1.34, 2.31) | 1.8 (1.34, 2.28) | 1.81 (1.34, 2.5) | 0.542 |
| PA, Median (Q1,Q3) | 188 (144, 226) | 193 (152, 235.5) | 149.5 (119.25, 205.5) | < 0.001 |
| AMY, Median (Q1,Q3) | 59 (44, 76) | 58 (44, 75) | 64.5 (43, 81.75) | 0.608 |
| LPS, Median (Q1,Q3) | 12.5 (8, 18.4) | 12.3 (8, 17.25) | 14 (7.88, 39.15) | 0.035 |
| WBC, Median (Q1,Q3) | 3.59 (2.48, 5.42) | 3.8 (2.74, 5.48) | 2.7 (1.42, 4.46) | < 0.001 |
| NEUT, Median (Q1,Q3) | 1.64 (0.99, 3.01) | 1.69 (1.12, 3.09) | 1.25 (0.42, 2.55) | 0.003 |
| RDW, Median (Q1,Q3) | 17 (15.2, 19.6) | 17.2 (15.35, 19.9) | 16.35 (14.22, 18.23) | 0.009 |
| hgb, Median (Q1,Q3) | 95 (85, 105) | 96 (86, 106) | 90 (83.25, 101.75) | 0.047 |
| plt, Median (Q1,Q3) | 192 (132, 279) | 207 (143.5, 293) | 134 (63.25, 215.5) | < 0.001 |
| LYMP, Median (Q1,Q3) | 1.28 (0.88, 1.88) | 1.33 (0.98, 1.89) | 0.79 (0.51, 1.88) | < 0.001 |
| HCT, Median (Q1,Q3) | 29.5 (26.3, 32.9) | 29.9 (26.6, 33.2) | 28 (25.02, 30.45) | 0.01 |
| crp, Median (Q1,Q3) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | < 0.001 |
| NLR, Median (Q1,Q3) | 1.37 (0.71, 2.85) | 1.39 (0.77, 2.71) | 1.31 (0.43, 3.27) | 0.491 |
| PLR, Median (Q1,Q3) | 140 (90.7, 247.3) | 140 (93.47, 230.29) | 143.94 (66.65, 284.84) | 0.877 |
| risk.classification.standard risk, n (%) |  |  |  | 0.281 |
| NO | 270 (84) | 218 (83) | 52 (90) |  |
| YES | 51 (16) | 45 (17) | 6 (10) |  |
| risk.classification.high risk, n (%) |  |  |  | 0.068 |
| NO | 276 (86) | 231 (88) | 45 (78) |  |
| YES | 45 (14) | 32 (12) | 13 (22) |  |
| risk.classification.new diagnosed, n (%) |  |  |  | < 0.001 |
| NO | 273 (85) | 242 (92) | 31 (53) |  |
| YES | 48 (15) | 21 (8) | 27 (47) |  |
| risk.classification.median risk, n (%) |  |  |  | < 0.001 |
| NO | 144 (45) | 98 (37) | 46 (79) |  |
| YES | 177 (55) | 165 (63) | 12 (21) |  |
| chemotherapy.phase.consolidation, n (%) |  |  |  | 1 |
| NO | 269 (84) | 220 (84) | 49 (84) |  |
| YES | 52 (16) | 43 (16) | 9 (16) |  |
| chemotherapy.phase.delayed intensification, n (%) |  |  |  | < 0.001 |
| NO | 221 (69) | 170 (65) | 51 (88) |  |
| YES | 100 (31) | 93 (35) | 7 (12) |  |
| chemotherapy.phase.induction, n (%) |  |  |  | < 0.001 |
| 0 | 269 (84) | 242 (92) | 27 (47) |  |
| 1 | 52 (16) | 21 (8) | 31 (53) |  |
| chemotherapy.phase.early intensification, n (%) |  |  |  | 0.004 |
| NO | 204 (64) | 157 (60) | 47 (81) |  |
| YES | 117 (36) | 106 (40) | 11 (19) |  |